GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Debt-to-Equity

GILD (Gilead Sciences) Debt-to-Equity : 1.26 (As of Sep. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Gilead Sciences Debt-to-Equity?

Gilead Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1,812 Mil. Gilead Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $21,437 Mil. Gilead Sciences's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $18,474 Mil. Gilead Sciences's debt to equity for the quarter that ended in Sep. 2024 was 1.26.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Gilead Sciences's Debt-to-Equity or its related term are showing as below:

GILD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.72   Med: 1.27   Max: 1.73
Current: 1.26

During the past 13 years, the highest Debt-to-Equity Ratio of Gilead Sciences was 1.73. The lowest was 0.72. And the median was 1.27.

GILD's Debt-to-Equity is ranked worse than
90.07% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs GILD: 1.26

Gilead Sciences Debt-to-Equity Historical Data

The historical data trend for Gilead Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Debt-to-Equity Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.09 1.73 1.27 1.19 1.09

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 1.09 1.44 1.28 1.26

Competitive Comparison of Gilead Sciences's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Gilead Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Debt-to-Equity falls into.



Gilead Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Gilead Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Gilead Sciences's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gilead Sciences  (NAS:GILD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Gilead Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711